article thumbnail

Sensome Announces Initiation of Clinical Trial Assessing Its Tissue Microsensor Technology in Peripheral Artery Disease

DAIC

Getty Images milla1cf Mon, 02/12/2024 - 15:22 February 12, 2024 — Sensome , a company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild Smart Guidewire in peripheral artery disease (PAD).

article thumbnail

Top 10: Must-reads from the Month of May

DAIC

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies 4. Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5.

article thumbnail

R3 Vascular Appoints Josh Smale as Vice President of Global Clinical and Scientific Affairs

DAIC

a Mountain View, CA-based developer of novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), has announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. Medical device company R3 Vascular Inc., Image courtesy: R3 Vascular Inc.

article thumbnail

Alternative access in transcatheter aortic valve replacement—an updated focused review

Frontiers in Cardiovascular Medicine

However, the prevalent use of TAVR on a diverse patient profile with different risk factors, such as peripheral artery disease, precluded the possibility of a transfemoral approach despite the improvement of valves and delivery systems technology.

article thumbnail

AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks

DAIC

The Efemoral Vascular Scaffold System (EVSS) offers a new approach to treating peripheral arterial occlusive disease (PAOD) by addressing the specific anatomic challenges and complex biomechanics of patients with athero-occlusive disease in the leg. The global burden of peripheral artery disease.

article thumbnail

Philips Enrolls First Patient in Clinical Trial for Integrated Single-Device to Treat PAD

DAIC

The care team there successfully treated a 78-year-old male with peripheral vascular disease using the Philips device. Developing and driving clinical evidence is crucial to improving care and guiding the adoption of new technologies like the Philips laser atherectomy and lithotripsy system,” said Drs.

article thumbnail

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. degradation of magnesium observed 12 months after implantation in coronary arteries.4 2,3 It has shown 99.6%